Cyclerion Therapeutics, Inc.
CYCN
$2.76
$0.2158.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -164.69% | -2,075.84% | 41.92% | 51.03% | 110.43% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.06% | 101.68% | 102.30% | 102.35% | -429.18% |
| Change in Net Operating Assets | 61.89% | 87.45% | 66.57% | 78.65% | 40.95% |
| Cash from Operations | 75.32% | 79.71% | 79.60% | 76.69% | 61.47% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Investing | -- | -- | -- | -100.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -29.60% | -30.45% | -- | 5,325.00% | 5,325.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Financing | -- | -72.63% | -- | -100.00% | -100.00% |
| Foreign Exchange rate Adjustments | 100.00% | -166.67% | -175.00% | -116.67% | -122.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -50.24% | -39.65% | 25.33% | 44.80% | 95.73% |